Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LY-3885125 by Eli Lilly and Co for Dyslipidemia: Likelihood of Approval
LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Dyslipidemia. According to GlobalData,...
LY-3885125 by Eli Lilly and Co for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Metabolic Dysfunction-Associated Steatotic Liver...
LY-3885125 by Eli Lilly and Co for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH)....